Fapon's Human/Cyno Cross-Reactive CD3/TCRVHHPlatform", Fapon Biopharma will showcase its proprietary CD3/TCR VHH-based T-cell engager (TCE) platform, an innovative approach designed to ...
). OMB Approval. OMB Number. 3235-0157. Expires. January 31, 2028. Estimated average burden. hours per response. 5.2 ... 1 ... 2 ... TCESpiritDirect Lending LLC published this content on January 30, 2026, and is solely responsible for the information contained herein.
In parallel, the AnTenGager™ TCE platform will remain open for global collaboration, enabling continued licensing and partnership opportunities ... 1. AnTenGager™ TCE Platform TCE platform with steric hindrance masking technology.